0001493152-23-043158.txt : 20231130 0001493152-23-043158.hdr.sgml : 20231130 20231130092052 ACCESSION NUMBER: 0001493152-23-043158 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20231130 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231130 DATE AS OF CHANGE: 20231130 FILER: COMPANY DATA: COMPANY CONFORMED NAME: bioAffinity Technologies, Inc. CENTRAL INDEX KEY: 0001712762 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731] IRS NUMBER: 465211056 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41463 FILM NUMBER: 231454267 BUSINESS ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 BUSINESS PHONE: 210-698-5334 MAIL ADDRESS: STREET 1: 22211 WEST INTERSTATE-10 STREET 2: SUITE 1206 CITY: SAN ANTONIO STATE: TX ZIP: 78257 8-K 1 form8-k.htm
false 0001712762 0001712762 2023-11-30 2023-11-30 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-11-30 2023-11-30 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-11-30 2023-11-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 30, 2023

 

BIOAFFINITY TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

22211 W Interstate 10

Suite 1206

San Antonio, Texas 78257

(210) 698-5334

(Address of principal executive offices and Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $.007 per share   BIAF   The Nasdaq Stock Market LLC
Tradeable Warrants to purchase Common Stock   BIAFW   The Nasdaq Stock Market LLC

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

On November 30, 2023, bioAffinity Technologies, Inc. (the “Company”) issued a press release announcing that the Centers for Medicare and Medicaid Services (“CMS”) has made a final determination for payment for CyPath® Lung, the Company’s noninvasive test for early-stage lung cancer, for the 2024 calendar year and that CyPath® Lung is now on CMS’ 2024 clinical laboratory fee schedule.

 

Based on the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommendation, in September 2023 CMS had previously released a preliminary payment decision for the Current Procedural Terminology (“CPT”) code specific to CyPath® Lung. For the calendar year 2024 Medicare Clinical Lab Fee Schedule, CMS has finalized the panel’s recommendation for CyPath® Lung for purposes of payment by Medicare. This payment information also serves as a reference for private payers and other public health insurance programs.

 

On November 30, 2023, the Company issued a press release disclosing the foregoing. A copy of the press release is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated by reference into this Item 7.01.The information in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

The press release attached as Exhibit 99.1 to this Current Report on Form 8-K includes “safe harbor” language pursuant to the Private Securities Litigation Reform Act of 1995, as amended, indicating that certain statements contained therein are “forward-looking” rather than historical.

 

The Company undertakes no duty or obligation to update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time if its management believes it is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases or through other public disclosures.

 

Item 8.01. Other Events.

 

On November 30, 2023, the “Company issued a press release announcing that CMS has made a final determination for payment for CyPath® Lung, the Company’s noninvasive test for early-stage lung cancer, for the 2024 calendar year and that CyPath® Lung is now on CMS’ 2024 clinical laboratory fee schedule.

 

In March 2023, the Company applied to the American Medical Association (“AMA”) for a CPT code specific to CyPath® Lung. At that time, Precision Pathology Services, now Precision Pathology Laboratory Services (“PPLS”), a subsidiary of the Company, billed for reimbursement of CyPath® Lung utilizing a combination of CPT codes associated with flow cytometry, including codes 88184, 88185 and 88188. Reimbursement amounts totaled approximately $300 using a combination of the flow cytometry codes that were descriptive of the test. Based on the existing flow cytometry codes, PPLS’ fee schedule set the price of the test at $905 based on Medicare reimbursement.

 

In June 2023, the AMA issued a CPT code for use in reimbursement of CyPath® Lung, effective October 1, 2023, for private payers and public health insurance programs, including Medicare and Medicaid. The CPT Proprietary Laboratory Analyses (PLA) code assigned to CyPath® Lung is 0406U with the descriptor “Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer.”

 

In July 2023, the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommended crosswalking, or using payment for a similar existing test, to determine the payment for the CPT code specific to CyPath® Lung. In September 2023, CMS released a preliminary payment decision in line with the Medicare Advisory Panel’s recommendation. The Company then submitted comments during the 30-day comment period in support of the preliminary decision to crosswalk the payment for CyPath® Lung to CPT code 0021U, which was $760 for the fourth quarter of 2023. Based on that payment, PPLS is currently billing $1,900 for CyPath® Lung. The 2024 Medicare Clinical Lab Fee Schedule will establish the 2024 Medicare payment for CyPath® Lung and serve as a reference for private payers and other public health insurance programs. In November 2023, CMS finalized the 2024 payment determination for CPT 0406U, effective January 1, 2024.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

  Exhibit No.   Description
       
  99.1   Press Release issued by bioAffinity Technologies, Inc. on November 30, 2022
  104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOAFFINITY TECHNOLOGIES, INC.
   
  By: /s/ Maria Zannes
    Maria Zannes
    President and Chief Executive Officer
     
Dated: November 30, 2023    

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

 

SAN ANTONIO, Texas (Nov. 30, 2023) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other lung diseases, today announced that the Centers for Medicare and Medicaid Services (CMS) has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

 

“CyPath® Lung, our noninvasive test for the detection of early-stage lung cancer, is now on CMS’ 2024 clinical laboratory fee schedule, a major milestone that facilitates reimbursement by both Medicare and private payers, which in turn should make our test even more attractive to both physicians and their patients at high risk for lung cancer,” bioAffinity Technologies President and CEO Maria Zannes said. “The CMS payment determination is an important achievement in our strategic plan to ramp up the commercialization of CyPath® Lung.”

 

Based on the Medicare Advisory Panel on Clinical Diagnostic Laboratory Tests recommendation, CMS previously released a preliminary payment decision for the Current Procedural Terminology (CPT) code specific to CyPath® Lung. For the calendar year 2024 Medicare Clinical Lab Fee Schedule, CMS finalized the panel’s recommendation for CyPath® Lung for purposes of payment by Medicare. This payment information also serves as a reference for private payers and other public health insurance programs.

 

In June 2023, the American Medical Association (AMA) issued the CPT Proprietary Laboratory Analyses (PLA) code 0406U for CyPath® Lung with the descriptor “Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4- carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer.” CMS released a preliminary payment decision in September 2023, agreeing with the Medicare Advisory Panel’s recommendation. In November 2023, CMS finalized the 2024 payment determination for CPT 0406U, effective January 1, 2024.

 

Physicians can order CyPath® Lung from Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. CyPath® Lung, a laboratory developed test (LDT), uses flow cytometry to identify cell populations in patient sputum that indicate malignancy. Automated data analysis developed using proprietary artificial intelligence can help determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin, TCPP, that is preferentially taken up by cancer and cancer-related cells. In a clinical trial, CyPath® Lung showed 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Half of all patients in the trial who had cancer were diagnosed in early Stages I or II.

 

The discovery of small pulmonary nodules as part of annual lung cancer screening using low dose computed tomography (LDCT) can be problematic to diagnose. Patients may be asked to “wait and see” if the next scan reveals the nodule has grown or proceed immediately with invasive procedures, including biopsy, that may turn out to be unnecessary. “Actionable results from CyPath® Lung may help doctors and their patients determine appropriate next steps for suspected cases of lung cancer,” Ms. Zannes said.

 

 
 

 

About bioAffinity Technologies, Inc.

 

bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and broad-spectrum cancer treatments. The Company’s first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. Research and optimization of the Company’s platform technologies are conducted in its laboratories at Precision Pathology and The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com and follow us on LinkedIn, Facebook and X.

 

Forward-Looking Statements

 

Certain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding CMS’ 2024 clinical laboratory fee schedule making the Company’s test even more attractive to both physicians and their patients at high risk for lung cancer and CyPath® Lung helping doctors and their patients determine appropriate next steps for suspected cases of lung cancer. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to benefit from the 2024 payment determination for CPT 0406U, the ability of the Company’s test to produce actionable results to help doctors and their patients determine appropriate next steps for suspected cases of lung cancer, and the other factors discussed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

 

Contacts

 

bioAffinity Technologies

Julie Anne Overton

Director of Communications

jao@bioaffinitytech.com

 

Investor Relations

Dave Gentry
RedChip Companies Inc.
1-800-RED-CHIP (733-2447) or 407-491-4498

BIAF@redchip.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end GRAPHIC 4 ex99-1_002.jpg begin 644 ex99-1_002.jpg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end EX-101.SCH 5 biaf-20231130.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 biaf-20231130_def.xml XBRL DEFINITION FILE EX-101.LAB 7 biaf-20231130_lab.xml XBRL LABEL FILE Class of Stock [Axis] Common Stock, par value $.007 per share Tradeable Warrants to purchase Common Stock Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 biaf-20231130_pre.xml XBRL PRESENTATION FILE XML 9 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 30, 2023
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 30, 2023
Entity File Number 001-41463
Entity Registrant Name BIOAFFINITY TECHNOLOGIES, INC.
Entity Central Index Key 0001712762
Entity Tax Identification Number 46-5211056
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 22211 W Interstate 10
Entity Address, Address Line Two Suite 1206
Entity Address, City or Town San Antonio
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78257
City Area Code 210
Local Phone Number 698-5334
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Common Stock, par value $.007 per share  
Title of 12(b) Security Common Stock, par value $.007 per share
Trading Symbol BIAF
Security Exchange Name NASDAQ
Tradeable Warrants to purchase Common Stock  
Title of 12(b) Security Tradeable Warrants to purchase Common Stock
Trading Symbol BIAFW
Security Exchange Name NASDAQ
XML 10 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001712762 2023-11-30 2023-11-30 0001712762 BIAF:CommonStockParValue.007PerShareMember 2023-11-30 2023-11-30 0001712762 BIAF:TradeableWarrantsToPurchaseCommonStockMember 2023-11-30 2023-11-30 iso4217:USD shares iso4217:USD shares false 0001712762 8-K 2023-11-30 BIOAFFINITY TECHNOLOGIES, INC. DE 001-41463 46-5211056 22211 W Interstate 10 Suite 1206 San Antonio TX 78257 210 698-5334 false false false false true Common Stock, par value $.007 per share BIAF NASDAQ Tradeable Warrants to purchase Common Stock BIAFW NASDAQ false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 3 24 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://bioaffinitytech.com/role/Cover Cover Cover 1 false false All Reports Book All Reports biaf-20231130.xsd biaf-20231130_def.xml biaf-20231130_lab.xml biaf-20231130_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "BIAF", "nsuri": "http://bioaffinitytech.com/20231130", "dts": { "schema": { "local": [ "biaf-20231130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "biaf-20231130_def.xml" ] }, "labelLink": { "local": [ "biaf-20231130_lab.xml" ] }, "presentationLink": { "local": [ "biaf-20231130_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 0, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 27 }, "report": { "R1": { "role": "http://bioaffinitytech.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "BIAF_TradeableWarrantsToPurchaseCommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20231130", "localname": "TradeableWarrantsToPurchaseCommonStockMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Tradeable Warrants to purchase Common Stock" } } }, "auth_ref": [] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "BIAF_CommonStockParValue.007PerShareMember": { "xbrltype": "domainItemType", "nsuri": "http://bioaffinitytech.com/20231130", "localname": "CommonStockParValue.007PerShareMember", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock, par value $.007 per share" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioaffinitytech.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-23-043158-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-043158-xbrl.zip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end